{"id":822,"date":"2020-06-11T10:17:02","date_gmt":"2020-06-11T10:17:02","guid":{"rendered":"https:\/\/imi-pharma.com\/?page_id=822"},"modified":"2024-09-03T17:08:47","modified_gmt":"2024-09-03T15:08:47","slug":"pharmacovigilance","status":"publish","type":"page","link":"https:\/\/imi-pharma.com\/?page_id=822","title":{"rendered":"Farmakovigjilenca"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\r\n<p>Farmakovigjilenca (PV) p\u00ebrcaktohet si shkenc\u00eb dhe aktivitet q\u00eb lidhet me zbulimin, vler\u00ebsimin, kuptimin dhe parandalimin e efekteve an\u00ebsore ose t\u00eb ndonj\u00eb problemi tjet\u00ebr q\u00eb lidhet me barnat. OBSH-ja krijoi Programin e saj p\u00ebr Monitorimin Nd\u00ebrkomb\u00ebtar t\u00eb Barnave n\u00eb p\u00ebrgjigje t\u00eb katastrof\u00ebs s\u00eb thalidomide-s\u00eb t\u00eb zbuluar n\u00eb vitin 1961. S\u00eb bashku me Qendr\u00ebn Bashk\u00ebpunuese t\u00eb OBSH-s\u00eb p\u00ebr Monitorimin Nd\u00ebrkomb\u00ebtar t\u00eb Barnave, Upsala, OBSH-ja promovoi PV n\u00eb nivelin shtetesh. N\u00eb fund t\u00eb vitit 2010, 134 vende ishin pjes\u00eb e Programit PV t\u00eb OBSH-s\u00eb. Q\u00ebllimet e PV-s\u00eb jan\u00eb t\u00eb p\u00ebrmir\u00ebsojn\u00eb kujdesin e pacientit dhe sigurin\u00eb e pacient\u00ebve n\u00eb lidhje me p\u00ebrdorimin e medikamenteve; dhe t\u00eb mb\u00ebshtesin programet e sh\u00ebndetit publik duke siguruar informacion t\u00eb besuesh\u00ebm dhe t\u00eb ekuilibruar p\u00ebr vler\u00ebsimin efektiv t\u00eb profilit rrezik-p\u00ebrfitim t\u00eb barnave<\/p>\r\n<p>&nbsp;<\/p>\r\n<p><strong><em>Tregohu vigjilent! Raporto!\u00a0\u00a0\u00a0\u00a0 <\/em><\/strong><strong><em>Kontakt: email: <\/em><\/strong><a href=\"mailto:phv@imi-pharma.com\"><strong><em>phv@imi-pharma.com<\/em><\/strong><\/a><\/p>\r\n<p><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Telefon: <a href=\"tel:+355 69 782 1502\">+355 69 782 1502<\/a><\/strong><\/p>\r\n<p><strong><em>Formulari i raportimit: <a href=\"https:\/\/imi-pharma.com\/wp-content\/uploads\/2022\/02\/formulari.pdf\" target=\"_blank\" rel=\"noopener\">Shkarko k\u00ebtu<\/a><\/em><\/strong><\/p>\r\n\r\n<p>&nbsp;<\/p>\r\n<p>[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/3&#8243;][media animation=&#8221;none&#8221; image=&#8221;899&#8243;][\/vc_column][\/vc_row]<\/p><\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text css=&#8221;&#8221;] Farmakovigjilenca (PV) p\u00ebrcaktohet si shkenc\u00eb dhe aktivitet q\u00eb lidhet me zbulimin, vler\u00ebsimin, kuptimin dhe parandalimin e efekteve an\u00ebsore ose t\u00eb ndonj\u00eb problemi tjet\u00ebr q\u00eb lidhet me barnat. OBSH-ja krijoi Programin e saj p\u00ebr Monitorimin Nd\u00ebrkomb\u00ebtar t\u00eb Barnave n\u00eb p\u00ebrgjigje t\u00eb katastrof\u00ebs s\u00eb thalidomide-s\u00eb t\u00eb zbuluar n\u00eb vitin 1961. S\u00eb bashku me Qendr\u00ebn [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-822","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/imi-pharma.com\/index.php?rest_route=\/wp\/v2\/pages\/822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imi-pharma.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/imi-pharma.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/imi-pharma.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/imi-pharma.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=822"}],"version-history":[{"count":15,"href":"https:\/\/imi-pharma.com\/index.php?rest_route=\/wp\/v2\/pages\/822\/revisions"}],"predecessor-version":[{"id":1686,"href":"https:\/\/imi-pharma.com\/index.php?rest_route=\/wp\/v2\/pages\/822\/revisions\/1686"}],"wp:attachment":[{"href":"https:\/\/imi-pharma.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}